{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Relapsed+or+Refractory+Follicular+Lymphoma&page=2", "query": { "condition": "Relapsed or Refractory Follicular Lymphoma", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Relapsed+or+Refractory+Follicular+Lymphoma&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-07-24T07:34:23.187Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01691898", "title": "A Study of Pinatuzumab Vedotin (DCDT2980S) Combined With Rituximab or Polatuzumab Vedotin (DCDS4501A) Combined With Rituximab or Obinutuzumab in Participants With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Follicular Lymphoma", "Diffuse Large B-Cell Lymphoma" ], "interventions": [ { "name": "Obinutuzumab", "type": "DRUG" }, { "name": "Pinatuzumab Vedotin", "type": "DRUG" }, { "name": "Polatuzumab Vedotin", "type": "DRUG" }, { "name": "Rituximab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Genentech, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 231, "start_date": "2012-09-27", "completion_date": "2019-02-07", "has_results": true, "last_update_posted_date": "2020-02-21", "last_synced_at": "2026-07-24T07:34:23.187Z", "location_count": 26, "location_summary": "Los Angeles, California • Stanford, California • Denver, Colorado + 21 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Fort Myers", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT01691898" }, { "nct_id": "NCT05100862", "title": "A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Relapsed/Refractory Follicular Lymphoma", "Marginal Zone Lymphoma" ], "interventions": [ { "name": "Zanubrutinib", "type": "DRUG" }, { "name": "Rituximab", "type": "DRUG" }, { "name": "Lenalidomide", "type": "DRUG" }, { "name": "Obinutuzumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "BeOne Medicines", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 799, "start_date": "2022-03-10", "completion_date": "2030-06", "has_results": false, "last_update_posted_date": "2026-07-23", "last_synced_at": "2026-07-24T07:34:23.187Z", "location_count": 49, "location_summary": "Fresno, California • Irvine, California • Los Alamitos, California + 42 more", "locations": [ { "city": "Fresno", "state": "California" }, { "city": "Irvine", "state": "California" }, { "city": "Los Alamitos", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05100862" }, { "nct_id": "NCT04587687", "title": "Brentuximab Vedotin and Bendamustine for the Treatment of Relapsed or Refractory Follicular Lymphoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Recurrent Follicular Lymphoma", "Refractory Follicular Lymphoma" ], "interventions": [ { "name": "Bendamustine Hydrochloride", "type": "DRUG" }, { "name": "Brentuximab Vedotin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of California, Davis", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 23, "start_date": "2020-12-04", "completion_date": "2028-05", "has_results": false, "last_update_posted_date": "2026-06-29", "last_synced_at": "2026-07-24T07:34:23.187Z", "location_count": 1, "location_summary": "Sacramento, California", "locations": [ { "city": "Sacramento", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04587687" }, { "nct_id": "NCT02464228", "title": "Investigation of Tipifarnib in Treatment of Subjects With Peripheral T-Cell Lymphoma (PTCL) That Have Not Responded to Standard Therapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Relapsed or Refractory Peripheral T-Cell Lymphoma" ], "interventions": [ { "name": "Tipifarnib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Kura Oncology, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 65, "start_date": "2016-02-25", "completion_date": "2021-03-31", "has_results": true, "last_update_posted_date": "2024-06-26", "last_synced_at": "2026-07-24T07:34:23.187Z", "location_count": 5, "location_summary": "Palo Alto, California • New Haven, Connecticut • Tampa, Florida + 2 more", "locations": [ { "city": "Palo Alto", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Tampa", "state": "Florida" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT02464228" }, { "nct_id": "NCT00726830", "title": "Methadone, Morphine, or Oxycodone in Treating Pain in Patients With Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Brain and Central Nervous System Tumors", "Chronic Myeloproliferative Disorders", "Leukemia", "Lymphoma", "Lymphoproliferative Disorder", "Multiple Myeloma and Plasma Cell Neoplasm", "Myelodysplastic Syndromes", "Myelodysplastic/Myeloproliferative Neoplasms", "Pain", "Precancerous Condition", "Unspecified Adult Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "methadone hydrochloride", "type": "DRUG" }, { "name": "morphine sulfate", "type": "DRUG" }, { "name": "oxycodone hydrochloride", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1, "start_date": "2009-03", "completion_date": "2010-10", "has_results": true, "last_update_posted_date": "2020-09-24", "last_synced_at": "2026-07-24T07:34:23.187Z", "location_count": 2, "location_summary": "Spartanburg, South Carolina • Houston, Texas", "locations": [ { "city": "Spartanburg", "state": "South Carolina" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00726830" }, { "nct_id": "NCT07343934", "title": "huCART19-IL18-eDHFR Cells in Relapsed/Refractory Follicular Lymphoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Relapsed or Refractory Follicular Lymphoma" ], "interventions": [ { "name": "huCART19-IL18-eDHFR cells", "type": "BIOLOGICAL" }, { "name": "[18F]Fluoropropyl-Trimethoprim", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "University of Pennsylvania", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 6, "start_date": "2026-05-18", "completion_date": "2042-11", "has_results": false, "last_update_posted_date": "2026-05-26", "last_synced_at": "2026-07-24T07:34:23.187Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT07343934" }, { "nct_id": "NCT00057343", "title": "Safety and Efficacy of Zevalin in the Treatment of Non-Hodgkin's Lymphoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Non-Hodgkin's Lymphoma" ], "interventions": [ { "name": "Zevalin (ibritumomab tiuxetan)", "type": "DRUG" }, { "name": "Rituxan (rituximab)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Biogen", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 400, "start_date": "2003-03", "completion_date": null, "has_results": false, "last_update_posted_date": "2006-09-12", "last_synced_at": "2026-07-24T07:34:23.187Z", "location_count": 67, "location_summary": "Huntsville, Alabama • Scottsdale, Arizona • Little Rock, Arkansas + 63 more", "locations": [ { "city": "Huntsville", "state": "Alabama" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Bakersfield", "state": "California" }, { "city": "Concord", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00057343" }, { "nct_id": "NCT01075321", "title": "Everolimus and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Adult Nasal Type Extranodal NK/T-cell Lymphoma", "Anaplastic Large Cell Lymphoma", "Angioimmunoblastic T-cell Lymphoma", "Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue", "Hepatosplenic T-cell Lymphoma", "Nodal Marginal Zone B-cell Lymphoma", "Peripheral T-cell Lymphoma", "Post-transplant Lymphoproliferative Disorder", "Recurrent Adult Burkitt Lymphoma", "Recurrent Adult Diffuse Large Cell Lymphoma", "Recurrent Adult Hodgkin Lymphoma", "Recurrent Adult T-cell Leukemia/Lymphoma", "Recurrent Grade 1 Follicular Lymphoma", "Recurrent Grade 2 Follicular Lymphoma", "Recurrent Grade 3 Follicular Lymphoma", "Recurrent Mantle Cell Lymphoma", "Recurrent Mycosis Fungoides/Sezary Syndrome", "Splenic Marginal Zone Lymphoma", "Waldenstrom Macroglobulinemia" ], "interventions": [ { "name": "everolimus", "type": "DRUG" }, { "name": "lenalidomide", "type": "DRUG" }, { "name": "laboratory biomarker analysis", "type": "OTHER" }, { "name": "polymorphism analysis", "type": "GENETIC" }, { "name": "immunohistochemistry staining method", "type": "OTHER" }, { "name": "microarray analysis", "type": "GENETIC" }, { "name": "fluorescence in situ hybridization", "type": "GENETIC" } ], "intervention_types": [ "DRUG", "OTHER", "GENETIC" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 58, "start_date": "2011-01-10", "completion_date": "2020-02-13", "has_results": true, "last_update_posted_date": "2020-10-22", "last_synced_at": "2026-07-24T07:34:23.187Z", "location_count": 2, "location_summary": "Scottsdale, Arizona • Rochester, Minnesota", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT01075321" }, { "nct_id": "NCT00575068", "title": "Safety and Efficacy of IDEC-114 in the Treatment of Non-Hodgkin's Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Non-Hodgkin's Lymphoma" ], "interventions": [ { "name": "IDEC-114", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Biogen", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 42, "start_date": "2002-01", "completion_date": "2010-11", "has_results": false, "last_update_posted_date": "2012-06-08", "last_synced_at": "2026-07-24T07:34:23.187Z", "location_count": 4, "location_summary": "Tucson, Arizona • Rochester, Minnesota • Buffalo, New York + 1 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Rochester", "state": "Minnesota" }, { "city": "Buffalo", "state": "New York" }, { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT00575068" }, { "nct_id": "NCT00436618", "title": "Everolimus in Treating Patients With Lymphoma That Has Relapsed or Not Responded to Previous Treatment", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Leukemia", "Lymphoma", "Lymphoproliferative Disorder" ], "interventions": [ { "name": "Everolimus", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 277, "start_date": "2005-08", "completion_date": "2019-10-09", "has_results": true, "last_update_posted_date": "2019-10-22", "last_synced_at": "2026-07-24T07:34:23.187Z", "location_count": 3, "location_summary": "Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT00436618" } ] }